Imaging Core

$136,824P50FY2012NSNIH

Feinstein Institute For Medical Research, Manhasset NY

Investigators

Linked publications, trials & patents

Paper 39737936 Paper 38853923 Paper 38766007 Paper 37660556 Paper 36054380 Paper 35325051 Paper 34148072 Paper 33839891 Paper 33502551 Paper 33246128 Paper 32925097 Paper 31872507 Paper 31813991 Paper 30776152 Paper 30417069 Paper 29914708 Paper 29536636 Paper 29432300 Paper 29167476 Paper 29088324 Paper 29046477 Paper 28971008 Paper 28215728 Paper 28188080 Paper 27699242 Paper 27571329 Paper 27544483 Paper 27207613 Paper 26626621 Paper 26449840 Paper 26377152 Paper 26036935 Paper 25675473 Paper 25338949 Paper 25296957 Paper 25280970 Paper 25260798 Paper 25178429 Paper 25037206 Paper 25036712 Paper 24963679 Paper 24498250 Paper 24453082 Paper 24364400 Paper 24345165 Paper 24129887 Paper 23851955 Paper 23671030 Paper 23578575 Paper 23467370 Paper 22951259 Paper 22941893 Paper 22710361 Paper 22553499 Paper 22491861 Paper 22406356 Paper 22357863 Paper 22323757 Paper 22206967 Paper 22126913 Paper 21849641 Paper 21771855

Abstract

The Imaging Core will provide essential support for the PET studies (Projects 1-3) and the MR studies (Project 2) proposed in this application. In these studies, multiple radiotracers will be administered intravenously to all research participants in conjunction with PET imaging. In Project 1, Parkinson's disease (PD) patients and healthy volunteer subjects will be scanned with [ [18] F]-FDG PET (to measure glucose metabolism), [[15] 0]-H20 PET (to visualize cerebral blood flow) and [ [82]Rb] PET (to assess blood brain barrier (BBB) permeability). In Project 2, PD patients will be scanned with [18] F-FDG (for glucose metabolism), [[11] C]-PIB (to detect protein aggregation), and [[18] F]-FPCIT (to trace striatal dopamine transporter binding). In Project 3, subjects will also undergo FPCIT PET imaging.

View original record on NIH RePORTER →